You are here

  • Home
  • Archive
  • Volume 6, Issue 2
  • Mixed results with baricitinib in biological-resistant adult-onset Still’s disease and undifferentiated systemic autoinflammatory disease

Article Text

Article menu

Download PDFPDF

Autoinflammatory disorders
Clinical case
Mixed results with baricitinib in biological-resistant adult-onset Still’s disease and undifferentiated systemic autoinflammatory disease
  1. Mark Kacar1,
  2. John Fitton2,
  3. Andrew K Gough3,
  4. Maya H Buch1,
  5. Dennis G McGonagle2 and
  6. Sinisa Savic2,4
  1. 1NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK
  2. 2Institue of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK
  3. 3Rheumatology, Harrogate District Hospital, Harrogate, UK
  4. 4Department of Clinical Immunology and Allergy, St James’s University Hospital, Leeds Teaching Hospitals NHS Trust, Leeds, UK
  1. Correspondence to Sinisa Savic; s.savic{at}leeds.ac.uk

Abstract

This clinical case series describes our experience with the use of Janus kinase 1/2 inhibitor baricitinib in two patients suffering from refractory adult-onset Still’s disease (AOSD) as well as in one case suffering from AOSD-like autoinflammatory disease in the context of myelodysplastic syndrome. All patients suffered from disease non-responsive to conventional Disease-modifying antirheumatic drugs (DMARDs) as well as biological therapies including interleukin (IL)-1 and IL-6 blockade, relying instead on high daily doses of prednisolone. We also report the first case of Pneumocystis jirovecii infection following baricitinib use.

  • Arthritis
  • Ankylosing Spondylitis
  • Psoriatic Arthritis
  • Adult Onset Still’s Disease
  • Fever Syndromes
  • Inflammation
  • DMARDs (biologic)
http://creativecommons.org/licenses/by-nc/4.0/

This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.

https://doi.org/10.1136/rmdopen-2020-001246

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Contributors Data collection—MK, JF. Preparing the manuscript—MK, SS. Contribution of clinical cases—MHB, AKG, DGM and SS. Manuscript editing and final approval—MK, JF, AKG MHB, DGM.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests Yes, there are competing interests for one or more authors and I have provided a Competing Interests statement in my manuscript.

    • Patient consent for publication Consent obtained directly from patient(s).

    • Provenance and peer review Not commissioned; externally peer reviewed.

    • Data sharing statement For further queries related to the cases presented here please contact the corresponding author.